![Tomas Hode](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Lu Alleruzzo | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 jaar |
Bobby Sandage | M | 70 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 9 jaar |
David Smoller | M | 60 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
P. Kirk Warden | M | - |
Missouri Biotechnology Association
| - |
J. Kenneth Charles Knowles | M | 77 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 4 jaar |
Derek Rapp | M | - |
Missouri Biotechnology Association
| - |
Saeid Esmaeilzadeh | M | 50 |
University of Stockholm
| 22 jaar |
Charlie Bolten | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Siu Kit Lam | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Joseph Raker | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Theresa Visarius | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Robert Nordquist | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Chen Wei | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
John Sagartz | M | 58 |
Missouri Biotechnology Association
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Carl M. Svernlöv | M | - |
University of Stockholm
| 2 jaar |
Sarah Al-Hajali | F | - |
University of Stockholm
| 1 jaar |
Pawel Zbigniew Szydlowski | M | 43 |
University of Stockholm
| 1 jaar |
Johan Carl Lundberg | M | 47 |
University of Stockholm
| 2 jaar |
Shams Jorjani | M | 41 |
University of Stockholm
| 2 jaar |
Pär Roosvall | M | 48 |
University of Stockholm
| 2 jaar |
Thomas Kidane | M | - |
University of Stockholm
| 2 jaar |
Kristoffer Eklund | M | 40 |
University of Stockholm
| 4 jaar |
Jesper Funck | M | 45 |
University of Stockholm
| 4 jaar |
Adam Lindberg | M | 46 |
University of Stockholm
| 1 jaar |
Declan Fitzgerald Mac Guinness | M | 58 |
University of Stockholm
| 3 jaar |
Jenny Cintra | F | 39 |
University of Stockholm
| 4 jaar |
Eva Nahari | F | - |
University of Stockholm
| 1 jaar |
Johanna Rutberg | F | 42 |
University of Stockholm
| 4 jaar |
Erik Norström | M | - |
University of Stockholm
| 4 jaar |
Sina Mostafavi | M | 42 |
University of Stockholm
| 3 jaar |
Johan Pellbäck | M | - |
University of Stockholm
| 3 jaar |
Carl Brusewitz | M | - |
University of Stockholm
| 3 jaar |
Awais Manzur Sumra | M | - |
University of Stockholm
| 1 jaar |
Silke Ernst | M | 57 |
University of Stockholm
| 3 jaar |
Elena Viktorovna Tumanova | F | 66 |
University of Stockholm
| 4 jaar |
Karl David Frykman | M | 52 |
University of Stockholm
| 6 jaar |
Mattias Stenberg | M | 47 |
University of Stockholm
| 2 jaar |
Martin Ragnar Andersson | M | 45 |
University of Stockholm
| 1 jaar |
Helena Westerberg | M | - |
University of Stockholm
| 1 jaar |
Sophia Evelina Bendz | F | 44 |
University of Stockholm
| 4 jaar |
Per Ingvar Backlund | M | - |
University of Stockholm
| 3 jaar |
Leif Vase Larsen | M | 61 |
University of Stockholm
| 2 jaar |
Daniel Nyhrén Edeen | M | 43 |
University of Stockholm
| 1 jaar |
Nanna Andersen | F | - |
University of Stockholm
| 4 jaar |
Martin Lundvall | M | - |
University of Stockholm
| 2 jaar |
Bertil Andersson | M | - |
University of Stockholm
| 7 jaar |
Tobias Hägglöv | M | 46 |
University of Stockholm
| 1 jaar |
Rickard Waldenlind | M | - |
University of Stockholm
| 4 jaar |
Erika Karin Elisabeth Henriksson | F | 43 |
University of Stockholm
| 2 jaar |
Marcus Jennekvist | M | 39 |
University of Stockholm
| 2 jaar |
Joakim Buddgård | M | 44 |
University of Stockholm
| 2 jaar |
Hanna Eiderbrant | F | 42 |
University of Stockholm
| 3 jaar |
Oskar Lindholm-Wu | M | 42 |
University of Stockholm
| 3 jaar |
Lova Unge | F | - |
University of Stockholm
| 5 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zweden | 41 | 75.93% |
Verenigde Staten | 13 | 24.07% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Tomas Hode
- Persoonlijk netwerk